Notice Number: NOT-DC-19-007
Key Dates
Release Date: September 4, 2019
First Available Due Date: October 5, 2019
Expiration Date: September 8, 2022
NOT-DC-18-007 Notice of NIDCD and NEI Interest in Supporting Research on Usher Syndrome
Issued by
National Institute on Deafness and Other Communication Disorders (NIDCD)
National Eye Institute (NEI)
Purpose
NOT-DC-18-007 is being reissued to provide new guidance on how to identify applications submitted in response to this NOSI so they can be identified.
Background:
Usher syndrome is the most common condition that affects both hearing and vision; sometimes it also affects balance. The major symptoms of Usher syndrome are deafness or hearing loss and an eye disease known as retinitis pigmentosa. The purpose of this notice is to express the joint interest of the National Institute on Deafness and Other Communication Disorders(NIDCD) and the National Eye Institute(NEI) in receiving applications for clinical, translational and basic research designed to ultimately prevent, restore or treat hearing loss, deafness, balance and vision loss caused by Usher syndrome.
Research Objectives:
Areas of Usher syndrome research encouraged through this Notice include, but are not limited to:
-
Translation of basic laboratory research findings into best clinical practices that preserve or restore the vision, hearing and balance in individuals with Usher syndrome
-
Studies related to disease pathogenesis and genetic factors that underlie structure, function, and the biology of Usher syndrome and their functional consequences for the purpose of developing clinical interventions
-
Development of model systems more reflective of the disease in humans
-
Studies that move beyond in vitro and animal models into humans
-
Strategies to accelerate the identification of molecular targets for therapeutic drug development
-
Collaborative studies between hearing and vision scientists that will identify common factors in the etiology of Usher syndrome that may lead to multi-purpose therapy development
-
Development of devices to improve quality of life
-
Studies that explore the role of non-Mendelian genetics, including epigenetic modifications, microRNA gene regulation, mitochondrial genetics and genetic modifier effects in Usher Syndrome
Application and Submission Information:
This notice applies to due dates on or after October 5, 2019 and subsequent due dates through September 8, 2022.
Submit applications for this initiative using one of the following funding opportunity announcements (FOAs) or any reissues of these announcement through the expiration date of this notice:
Activity Code |
FOA |
First Available Due Date |
U01 |
PAR-18-340 NIDCD Cooperative Agreement for Clinical Trials in Communication Disorders (U01 Clinical Trials Required) |
October 21, 2019 |
R01 |
PA-18-334 NIDCD Clinical Trials in Communication Disorders (R01 Clinical Trial Required) |
October 5, 2019 |
R01 |
PA-19-056 NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed) |
October 5, 2019 |
R01 |
PA-18-351 NEI Human Subjects Mechanistic and Minimal Risk Studies (R01 Clinical Trial Optional) |
October 5, 2019 |
R21 |
PA-19-092 NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required) |
October 16, 2019 |
R21 |
PA-19-053 NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed) |
October 16, 2019 |
R21 |
PA-18-500 NEI Human Subjects Mechanistic and Minimal Risk Studies (R21 Clinical Trial Optional) |
October 16, 2019 |
R21 |
PAR-18-487 NIDCD Early Career Research(ECR) Award (R21 - Clinical Trials Optional) |
October 28, 2019 |
R24 |
PAR-18-707 NEI Translational Research Program (TRP) on Therapy for Visual Disorders (R24 Clinical Trial Optional) |
January 25, 2020 |
R01 |
PAR-18-533 NIDCD Research Grants for Translating Basic Research into Clinical Tools (R01- Clinical Trials Optional) |
October 18, 2019 |
P50 |
PAR-19-137 NIDCD Clinical Research Center Grant (P50 - Clinical Trials Optional) |
October 4, 2019 |
UG1 |
PAR-18-521 NEI Collaborative Clinical Vision Research Project: Coordinating Center Grant (UG1 Clinical Trial Required) |
January 25, 2020 |
UG1 |
PAR-18-522 UG1 Clinical Research Cooperative Agreements - Single Project |
January 25, 2020 |
UG1 |
PAR-18-523 UG1 Clinical Research Cooperative Agreements Single Project |
January 25, 2020 |
Other Parent FOAs for Research (R), Career Development (K), and Fellowship (F) awards in which NIDCD and NEI participate can also be used (see "Parent Announcements (for Unsolicited or Investigator Initiated Applications)": https://grants.nih.gov/grants/guide/parent_announcements.htm).
All instructions in the SF424 (R&R) Application Guide and the funding opportunity announcement used for submission must be followed, with the following additions:
- For funding consideration, applicants must include "NOT-DC-19-007" (without quotation marks) in the Agency Routing Identifier field (box 4b) of the SF424 R&R form. Applications without this information in box 4b will not be considered for this initiative.
Inquiries
Please direct all inquiries to:
Bracie Watson, Jr., Ph.D.
National Institute on Deafness and Other Communication Disorders
Telephone: 301-402-3458
Email: watsonb@nidcd.nih.gov
Grace Shen, Ph.D.
National Eye Institute
Telephone: 301-451-2020
Email: sheng@nei.nih.gov
and Human Services (HHS)
